Form DEFA14A Spyre Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'
April 13, 2026 8:21 AM EDTLeerink Partners analyst Thomas J. Smith reiterated an Outperform rating on Spyre (NASDAQ: SYRE).
The analyst comments "SYRE (OP) announced positive topline results from the open-label SPY001 (anti-47) monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC). Importantly, SPY001 demonstrated class-leading efficacy on the study's primary and key secondary endpoints, showing an impressive -9.2pt reduction from baseline on the primary RHI endpoint and a 40% clinical remission rate at week 12 - both data points suggesting differentiated efficacy relative to TAK's (NR)... More
Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'
April 13, 2026 7:46 AM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $115.00 price target on Spyre (NASDAQ: SYRE).
The analyst comments "Spyre announced topline results for SPY001's monotherapy study in SKYLINE-UC Part A (n~130). Across multiple endpoints (RHI from baseline, clinical remission, endoscopic improvement), SPY001/47 consistently outperformed TAK's Entyvio (both Week 6 & 14 comps), with most notable efficacy outcome of 40% clinical remission at week 12 (Fig 1 & 2). The induction CR data is one of the highest we have seen and significantly... More
